{"classes":[{"categories":[{"measurements":[{"comment":"PFS was not reached for Cohorts A and B due to fewer number of participants with events.","groupId":"OG000","lowerLimit":"1285.0","upperLimit":"NA","value":"NA"},{"comment":"PFS was not reached for Cohorts A and B due to fewer number of participants with events.","groupId":"OG001","lowerLimit":"1028.0","upperLimit":"NA","value":"1809.0"},{"groupId":"OG002","lowerLimit":"335.0","upperLimit":"714.0","value":"432.0"},{"groupId":"OG003","lowerLimit":"186.0","upperLimit":"1847.0","value":"959.0"},{"groupId":"OG004","lowerLimit":"55.0","upperLimit":"169.0","value":"111.0"},{"groupId":"OG005","lowerLimit":"55.0","upperLimit":"150.0","value":"83.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"48"},{"groupId":"OG005","value":"46"}],"units":"Participants"}],"description":"PFS is defined as the interval from the first dose of study treatment until the criteria for progression or death are met, censored at the last response assessment. Progression from CP is reported as death, development of AP or BP, loss of CHR (in the absence of cytogenetic response), confirmed by development in complete blood counts (CBCs) at least 4 weeks apart, loss of MCyR, increasing WBC in participant without CHR defined by doubling of WBC to \\>20K on 2 occasions at least 4 weeks apart; Progression from AP is reported as death, development of confirmed BP, loss of previous major or minor hematologic response over a 2-week period, no decrease from baseline levels in percentage blasts in peripheral blood or BM on all assessments over a 4-week period; Progression from BP or Ph+ ALL is reported as death, increasing blasts in peripheral blood or BM over a 4 week period.","dispersionType":"95% Confidence Interval","groups":[{"description":"CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG000","title":"Cohort A: CP-CML R-I"},{"description":"CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG001","title":"Cohort B: CP-CML With T315I Mutation"},{"description":"AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG002","title":"Cohort C: AP-CML R-I"},{"description":"AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG003","title":"Cohort D: AP-CML With T315I Mutation"},{"description":"BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG004","title":"Cohort E: BP-CML/Ph+ ALL R-I"},{"description":"BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG005","title":"Cohort F: BP-CML or Ph+ ALL With T315I Mutation"}],"paramType":"MEDIAN","populationDescription":"Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib.","reportingStatus":"POSTED","timeFrame":"Every 12 weeks ± 2 weeks from last dose of study drug or the investigator/participant decision to discontinue treatment, whichever occurred later (Up to approximately 96 months after last dose)","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"days"}